Literature DB >> 11905725

Immunotherapy of cancer with alloreactive lymphocytes.

S Slavin1.   

Abstract

Immunotherapy of cancer with alloreactive lymphocytes is the mainstay of treatment, especially in haematological malignant disease. With donor lymphocyte infusion for immunotherapy, it is essential to induce host-versus-graft tolerance to ensure that the donor lymphocytes are accepted. Engraftment of haemopoietic cells of donor origin can be accomplished with reduced-intensity conditioning. Reducing transplant-related mortality by simplifing the stem-cell transplant procedure with a reduced-intensity regimen, particularly non-myeloablative conditioning, may have great potential for the treatment of malignant and non-malignant disorders.

Entities:  

Mesh:

Year:  2001        PMID: 11905725     DOI: 10.1016/S1470-2045(01)00455-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  3 in total

Review 1.  Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.

Authors:  Shimon Slavin; Arnon Nagler; Michael Y Shapira; Mehmet Aker; Cividalli Gabriel; Reuven Or
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

Review 2.  Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.

Authors:  Shimon Slavin
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

3.  Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.

Authors:  S Ash; J Stein; N Askenasy; I Yaniv
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.